Located on the grounds of the luxury Bella Sirena resort ( www.rctherapy.net/bella-sirena-resort ), RCT focuses on regenerative cellular therapy and natural pharmaceutical-quality bio-medications to optimize one’s energy and cell nutrition.

These processes stimulate stem cells using peptides and peptones. The effect is to eradicate the signs and symptoms of diseases more quickly and more effectively than medulla stem cell protocols. Each of the treatments exerts an effective preventative and curative action. “This occurs because the peptide and peptone treatments allow us to specifically target the organ that is affected,” stated Dr. Castro.

The use of peptides and peptones stimulates the patient’s stem cells, bringing results with unparalleled speed and intensity. The treatments are non-invasive and do not present any risk to the patient’s health, nor are there any negative secondary side effects or allergic reactions.

RCT’s peptide and peptone laboratories have been in their fields for over thirty years. “These laboratories continue to develop new therapies which have succeeded in having the dysfunctional cells of the recipient regenerate for their repair and revitalization within the strictest and most rigorous controls exacted by bio-safety,” says Dr. Castro.

In addition to treating symptoms, RCT’s bio-medications empower one’s cell tissue structure and organs, avoiding the connection of the symptoms to the disease, thus making the body fit to withstand functional stress loads during the treatment. All of this is done through correcting the biological process of the disease’s source and its side effects.

The two treatments receiving the most attention at RTC are the Peptide and E+ Peptide Cancer Vaccine. These treatments are now being used to treat:
* Diabetes
* Anti-Aging
* Rheumatoid Arthritis
* Cirrhosis
* Cancer
* Scleroderma
* Leukemia
* Lupus
* Kidney Failure
* Osteoporosis.

RCT’s E+ Peptide Cancer Vaccine is the key to tumor destruction. By conducting an exchange of information through the p53 gene, the gene then orders cellular self-destruction rather than multiplication, a process called apoptosis.

RCT does not offer services stateside, but the procedures are common in other parts of the world. “Our treatments have the phone ringing off the hook,” says Dr. Castro, “and we’re developing a backlog to service as many patients as we can.”

More information is available at http://www.rctherapy.net and contact@rctherapy.net, 480-626-4845 (USA office) or 638-382-8011 (Mexico office). An informational brochure may be downloaded at http://www.rctherapy.net/thankyou/RCT-BROCHURE.pdf .

News Source: Regenerative Cellular Therapy :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

Based on the adaptive Phase I/II study design, which included an FDA allowance for surgical intervention to be added to the treatment protocol in cases where repeated Rexin-G infusions had served to control the cancer and halt disease progression, the report describes the use of Rexin-G as both neoadjuvant therapy (before surgery) and as adjuvant therapy (after surgery) to prevent post-surgical spread and disease recurrence. Remarkably, the excised tumor(s) showed the process of Rexin-G accumulation within the tumors, as well as the molecular mechanisms of tumor cell destruction, with an unprecedented level of histological high-definition.

The landmark paper, published in the latest issue of Oncology Reports (Open Access, 24: 829-833, 2010) demonstrates the physical accumulation of the intravenous Rexin-G nano-medicine within the metastatic tumor prior to its surgical excision.

It additionally reveals the selective accumulation of the Rexin-G nanoparticles on the surfaces of the target cells, i.e., pancreatic cancer cells and their proliferative vasculature, which is a distinctive property of the tumor-targeted nanotechnology platform. Using elegant immunohistochemistry to identify the process of active cell death (apoptosis) enforced by Rexin-G, the molecular mechanisms of precision tumor-targeting and selective cell death have never been more vividly displayed.

It bears mentioning that the pancreatic cancer patient highlighted in this histological study is currently in surgical remission, with no new lesions during Rexin-G treatment and no disease recurrence going on six months after the Rexin-G / Surgical Excision / Rexin-G treatment combination.

About Epeius Biotechnologies:

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company that is bringing the latest advancements in genetic medicine to the cancer patient with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems. Rexin-G(R) is currently approved for the treatment of all chemotherapy-resistant solid tumors by the Philippine FDA.

To learn more about our lead products and/or our pipeline of proprietary biotechnologies, please visit us at http://www.epeiusbiotech.com . For recent papers, expert reviews, clinical reports in oncology and molecular therapy, etc., see the “Publications” section.

Plain text copy of press release (and media contact)

PDF copy of press release (and media contact)


STORY REFERENCES: To Reach, Perchance to Kill the Cancer: A Soliloquy from Epeius Nanotechnologies Opposes that ‘Sea of Troubles’, Oncology Reports, Rexin-G in chemo-resistant metastatic pancreatic cancer, targeted genetic medicine, histological study, U.S. Phase I/II clinical trials, biotech, pharma, cancer research, treatment protocol, oncology products, molecular therapy, Erlinda M. Gordon, M.D.

Shawn McGuan, CEO of LifeModeler, Inc., said the new software entry will “greatly shorten the time it takes to get helpful devices into the hands of surgeons who can radically alter the lifestyles of an aging population.”

The company, which has consistently supported the orthopedic community with virtual modeling products such as LifeMOD™ and KneeSIM™, sees this new software as having an overall influence similar to that of its popular knee product.

“It will provide completely new insight for surgeons and researchers who are involved in spinal surgery, spinal cord stimulation implants, and artificial disc replacement,” said McGuan. “That potential for affecting the lives of so many will see LumbarSIM’s use grow very quickly,” he predicted.

The new product, which automatically creates a detailed lumbar spine model and separates it into individual vertebral segments and disc forces, integrates easily into the company’s well-respected LifeMOD software. Its eventual applications in the orthopedic arena are numerous, especially when attempting to pre-evaluate surgical options such as spinal fusion, discectomy, and laminectomy.

The simplicity of adapting to LumbarSIM’s architecture is a feature that LifeModeler’s engineers focused on so that it could easily serve as a design tool for orthopedic device developers. Much of the software’s operational characteristics mirror the workflow that is commonly found on a personal computer.

“It’s somewhat like using ‘favorites’ on your desktop,” said McGuan.

Many of the common tasks have been streamlined and the modeling language is more user-centric, making all of the workflow customizable to fit specific needs. This makes LumbarSIM easily learned, and easily applied.

Reports generated by the software offer increased sophistication, including the incorporation of hypertext, plots, live video, and model animation.

According to McGuan, the software has built-in orthopedic-specific plots based on published spinal data, saving valuable research and development time by automating plot development.

The company’s LifeMOD product is used by more than 600 corporate clients and hundreds of universities and research institutions worldwide, said McGuan. He also indicated that many of their orthopedic industry clients are realizing productivity increases up to 20 percent while also decreasing development costs by as much as 40 percent-simultaneously enhancing innovative techniques and reducing risk.

He sees the application for this new lumbar product as continuing that trend. And with tens of millions of lower back pain sufferers, it’s getting to market at just the right time.

LifeModeler, Inc. can be contacted at 949-366-6829, and additional information on the company and its products can be found at www.lifemodeler.com .

News Source: LifeModeler, Inc. :: This press release was issued by Send2Press® and is Copyright © 2009 Neotrope® News Network – all rights reserved.

The clinical development of Rexin-G worldwide has been equally remarkable. Beginning with the most serious and life-threatening forms of pancreatic cancer, Rexin-G has demonstrated unprecedented single-agent efficacy in metastatic cancers of the colon, breast, skin, lung, and bone in a progressive program of expanded access that continues to achieve historic milestones. Eschewing any trappings of personal accomplishment, Epeius gives credit to the dedication and efforts of the many pioneering oncologists, the progressive medical institutions, and the conscientious regulatory agencies who have all served to guide Rexin-G, with its elegant tumor-targeting nanotechnologies, to the bedside. Most recently, Rexin-G has been approved in the Philippines for the treatment of all solid tumors that are refractory to standard chemotherapies.

In addition to developing the first and so far only tumor-targeted genetic medicine that has been validated in the clinic, Epeius Biotechnologies has assumed the daunting responsibilities of advancing these enabling platform technologies safely and effectively through an arduous array of regulatory hurdles and medical proofs-of-principle that are required for a radically new medicine. Initial Phase I safety studies established the general safety of Rexin-G, followed by Phase I/II efficacy studies where optimal clinical protocols were established for each particular type of tumor.

The importance of these progressive dose-escalation studies-which clearly establish safety before escalating to more potent tumoricidal dose levels-is of primary concern in the development of a new genetic medicine like Rexin-G. Moreover, the establishment of a functional dose-response relationship is of fundamental significance, not only in terms of basic pharmacology, but in establishing the physiological mechanisms-of-action that are of major importance in determining the predictability of a new anti-cancer agent and ultimately in gaining full regulatory approval for Rexin-G in the United States.

Based on the scientific and medicinal merits of Rexin-G, as well as the rarity, seriousness, and lack of effective therapies for metastatic cancers, the granting of a third Orphan Drug Designation by the FDA at this time is both encouraging and confirmatory. Orphan Drug Designation provides important economic incentives and powerful market protections that encourage the development of innovative products in the cancer field. U.S. Orphan Drug Designation provides seven years of market exclusivity for Rexin-G, a reduction in fees and taxes, and additional regulatory support for ongoing R&D initiatives.

About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about our pipeline of biotechnologies and products that are currently available for licensing and clinical development, please visit our website, www.epeiusbiotech.com.

For more information about Rexin-G, on-going clinical trials in the USA and abroad, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.

News Source: Epeius Biotechnologies Corporation :: This press release was issued by Send2Press® and is Copyright © 2008 Neotrope® News Network – all rights reserved.

The Global Pharma R&D Summit 2007 (www.globalpharmasummit.com), which will be held at the Boston Marriott Hotel, Newton MA 02466 USA, on October 22-23, 2007, showcases cutting-edge biotechnology and pharmaceutical companies that are developing superior technologies and products in healthcare and healthcare related areas, and offers a forum to meet with suppliers, service providers, opinion leaders, and representatives from other leading pharmaceutical and biotechnology companies worldwide. The Keynote Address provides an opportunity for Epeius to update the industry in regard to its recent clinical developments and global partnering initiatives to expedite the international development of Rexin-G, which is currently in clinical trials in Europe, Japan, and ASEAN member countries, as well as the United States.

The focus on Epeius Biotechnologies during National Breast Cancer Awareness Month, is apropos-for the company has just opened an Advanced Phase I/II trial for chemo-resistant breast cancer in San Marino and Santa Monica California. Rexin-G, has received Orphan Drug Status from the FDA based on unprecedented demonstrations of single-agent efficacy in treating pancreatic cancer. Subsequently, the company has gained federal support and private agency support to continue their landmark clinical trials in the United States using intravenous Rexin-G for breast cancer that afflicts one of 4 women and sarcoma that afflicts teenagers and young adults. These Phase I/II clinical trials with adaptive trial designs will facilitate the development of Rexin-G for breast cancer, sarcoma and pancreatic cancer in the United States.

In addition to leading the advancement of bioscience and medicine from “the bench to the bedside” in a manner that is unprecedented in modern times, Dr. Hall and the senior management team of Epeius Biotechnologies continues to raise the bar for the biopharmaceutical industry in terms of corporate productivity, R&D efficiency, and significant drug development. Having (i) gained exclusive licensing rights for all of the tumor targeting and molecular-genetic technologies embodied in Rexin-G, (ii) conducted international clinical trials that validated the lead product, (iii) advanced the yield of biopharmaceutical GMP through a series of major technological innovations, (iv) attained both Orphan Drug Status and Expanded Access Designation through various regulatory authorities, (v) generated the company’s first million dollars in revenues through product sales, and (vi) initiated a bold corporate outreach program that facilitated the development of strategic alliances and corporate partnering, Dr. Hall’s invited Keynote Address at the Global Pharma R&D Summit will be a tough act to follow.

About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. Credited with innovations ranging from oncogene discovery, to designer therapeutic genes, to pathotropic (disease-seeking) targeting, to high-performance vector engineering, to advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to “launch” its enabling platform technologies for the benefit of cancer patients worldwide. Rapid advances in clinical drug development provide Epeius with a unique opportunity for early revenues from the exportation and sale of its lead product to the Philippines and reciprocating Southeast Asian countries-thus demonstrating the high growth potential of a small biotechnology company while maintaining the lowered risk profile of a biopharmaceutical company with a high-value, late-stage product.

To learn more about Rexin-G and Epeius’ pipeline of proprietary compounds currently available for partnership or clinical trials, please visit us at www.epeiusbiotech.com.

News Source: Epeius Biotechnologies :: This press release was issued by Send2Press® and is Copyright © 2007 Neotrope® News Network – all rights reserved.

SAN MARINO, Calif. – Oct. 11, 2006 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Dr. Frederick Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak at the upcoming Global Pharmaceutical Research & Development Summit held on Oct. 24 at 4:10 p.m. (PT) in Anaheim, Calif. Dr. Hall will present the current status of global development and the broad pharmaceutical indications for the company’s innovative targeting technology platform that has enabled Epeius to develop Rexin-G(TM), the world’s first tumor-targeted gene therapy system that actually works in humans. Rexin-G was recently approved for the treatment of all solid tumors in the Philippines and is currently in clinical trials at several medical centers in the U.S., Manila, and Japan.

In addition, Dr. Erlinda Maria Gordon, Vice President of Operations and Medical Affairs, will be chairing a session on genetic medicine at the upcoming Oncology Leaders Forum on Oct. 31 at 12:50 p.m. (PT) at the Torrey Pines Hilton Hotel, in La Jolla Calif. Dr. Gordon’s session will discuss the impact of targeted gene delivery systems, specifically Rexin-G, on the treatment of chemo-resistant cancer types, which comprise about 80 percent of the cancer population.

The Global Pharmaceutical Research & Development Summit, which will be held on Oct. 23-25, is attended by the world’s leading drug research and development professionals and features invited speakers from cutting edge biotechnology companies, top executives from the FDA and the World Health Organization (WHO), leading academic researchers and decision makers in large pharmaceutical companies. The Oncology Leaders Forum, held on Oct. 30-Nov. 1, is an annual meeting for the industry leaders driving the development, approval, and launch of novel cancer therapies of all classes. Both conferences offer the opportunity for industry leaders to discuss with Epeius executives potential partnering opportunities for the expedited development of their lead product, Rexin-G, and for the development of new products in the fields of oncology and cardiovascular disease.

Rexin-G has received Orphan Drug Status based on unprecedented demonstrations of single-agent efficacy in pancreatic cancer. Subsequently, the company gained federal support to continue their landmark clinical trials using intravenous infusions of Rexin-G for treating metastatic cancer. Further, Rexin-G has gained accelerated marketing approval in the Philippines for treating all solid tumors that are resistant to chemotherapy.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. Credited with innovations ranging from oncogene discovery, to designer-gene therapy, to pathotropic (disease-seeking) targeting, to high-performance vector engineering, to advanced GMP and bioprocess development, Epeius Biotechnologies is well positioned to “launch” its enabling platform technologies for the benefit of cancer patients worldwide.

Rapid advances in clinical drug development provide Epeius with a unique opportunity for early revenues from the exportation and sale of its lead product to the Philippines and reciprocating Southeast Asian countries-thus demonstrating the high growth potential of a small biotechnology company while maintaining the lowered risk profile of a biopharmaceutical company with a high-value, late-stage product.

To learn more about Rexin-G(TM) and Epeius’ pipeline of proprietary compounds currently available for partnership, please visit us at www.epeiusbiotech.com.

News Source: Epeius Biotechnologies :: This press release was issued by Send2Press® and is Copyright © 2006 Neotrope® News Network – all rights reserved.